Search

Your search keyword '"Babjuk, Marek"' showing total 253 results
Start Over Author "Babjuk, Marek" Publication Type Academic Journals
253 results on '"Babjuk, Marek"'

2. Preoperative Plasma Insulin-Like Growth Factor-I and Its Binding Proteins-Based Risk Stratification of Patients Treated With Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma

Author

Kardoust Parizi, Mehdi, Rouprêt, Morgan, Singla, Nirmish, Teoh, Jeremy Yuen-Chun, Chlosta, Piotr, Babjuk, Marek, Abufaraj, Mohammad, Margulis, Vitaly, D'Andrea, David, Klemm, Jakob, Matsukawa, Akihiro, Laukhtina, Ekaterina, Fazekas, Tamas, Karakiewicz, Pierre I., Bhanvadia, Raj, Gontero, Paolo, and Shariat, Shahrokh F.

Published
2024
Full Text
View/download PDF

3. En bloc resection of bladder tumour: the rebirth of past through reminiscence

Author

Teoh, Jeremy Yuen-Chun, D’Andrea, David, Gallioli, Andrea, Yanagisawa, Takafumi, MacLennan, Steven, Nicoletti, Rossella, Fai, Ng Chi, Maffei, Davide, Hurle, Rodolfo, Lusuardi, Lukas, Malavaud, Bernard, Miki, Jun, Kramer, Mario, Mostafid, Hugh, Enikeev, Dmitry, Babjuk, Marek, Breda, Alberto, Shariat, Shahrokh, Gontero, Paolo, and Herrmann, Thomas

Published
2023
Full Text
View/download PDF

6. Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial

Author

Lopes, Renato D, Higano, Celestia S, Slovin, Susan F, Nelson, Adam J, Bigelow, Robert, Sørensen, Per S, Melloni, Chiara, Goodman, Shaun G, Evans, Christopher P, Nilsson, Jan, Bhatt, Deepak L, Clarke, Noel W, Olesen, Tine K, Doyle-Olsen, Belinda T, Kristensen, Henriette, Arney, Lauren, Roe, Matthew T, Alexander, John H, Mol-Arts, Mirjam, Mansor-Lefebvre, Samreen, Zubovskiy, Konstantin, Blemings, Allan, Dugi, Klaus, Bloomfield, Gerald, Kontos, Chris, DeVore, Adam, Jordan, Dedrick, Kolls, Bradley, Matthews, Robin, Mehta, Rajendra, Povsic, Thomas J, Morse, Michael, Mahaffey, Kenneth W, Halabi, Susan, Leong, Darryl, Klotz, Laurence, Fleshner, Neil, Jansz, Godfrey, Giddens, Jonathan, Egerdie, Russell, Chin, Joseph, Zadra, Joseph, Casey, Richard, Simard, Jean, Niazi, Tamim, Martin, André-Guy, Babjuk, Marek, Hajek, Jaroslav, Klecka, Jiri, Kubes, Jiri, Schraml, Jan, Jakesova, Jitka, Vanasek, Jaroslav, Melichar, Bohuslav, Seikkula, Heikki, Abdiche, Manouar Samir, Colombel, Marc, Debourdeau, Philippe, Robert, Gregoire, Villers, Arnauld, Ploussard, Guillaume, Pradere, Benjamin, Bruyere, Franck, Descotes, Jean-Luc, Ouzaid, Idir, Winter, Alexander, Hanitzsch, Herbert, Sperling, Herbert, Eckert, Ralf, Hammerer, Peter, Stagge, Elke, Seseke, Florian, Szymula, Silvio, Bamias, Aristotelis, Thanos, Anastasios, Hatzimouratidis, Konstantinos, Mamoulakis, Charalambos, Kalofonos, Haralabos, Oszukowska, Elzbieta, Madziarska, Katarzyna, Fijuth, Jacek, Obarzanowski, Mateusz, Alekseev, Boris, Atduev, Vagif, Pushkar, Dmitri, Veliev, Evgeniy, Zyryanov, Alexander, Petrov, Sergey, Kopyltsov, Evgeny, Kozlov, Vadim, Macko, Ladislav, Dubravicky, Jozef, Polak, Richard, Mir, Obaidullah, Vargovcak, Marek, Mincik, Ivan, Kliment, Jan, Goncalves, Frederico, Mikulas, Juraj, and Sokol, Roman

Subjects
Cancer, Clinical Trials and Supportive Activities, Patient Safety, Aging, Prostate Cancer, Urologic Diseases, Cardiovascular, Clinical Research, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Good Health and Well Being, Aged, Humans, Leuprolide, Male, Oligopeptides, Prospective Studies, Prostatic Neoplasms, agonists, atherosclerosis, cardiotoxicity, drug therapy, gonadotropin-releasing hormone, prostatic neoplasms, PRONOUNCE Study Investigators, Cardiorespiratory Medicine and Haematology, Clinical Sciences, Public Health and Health Services, Cardiovascular System & Hematology
Abstract

BackgroundThe relative cardiovascular safety of gonadotropin-releasing hormone (GnRH) antagonists compared with GnRH agonists in men with prostate cancer and known atherosclerotic cardiovascular disease remains controversial.MethodsIn this international, multicenter, prospective, randomized, open-label trial, men with prostate cancer and concomitant atherosclerotic cardiovascular disease were randomly assigned 1:1 to receive the GnRH antagonist degarelix or the GnRH agonist leuprolide for 12 months. The primary outcome was the time to first adjudicated major adverse cardiovascular event (composite of death, myocardial infarction, or stroke) through 12 months.ResultsBecause of slower-than-projected enrollment and fewer-than-projected primary outcome events, enrollment was stopped before the 900 planned participants were accrued. From May 3, 2016, to April 16, 2020, a total of 545 patients from 113 sites across 12 countries were randomly selected. Baseline characteristics were balanced between study groups. The median age was 73 years, 49.8% had localized prostate cancer; 26.3% had locally advanced disease, and 20.4% had metastatic disease. A major adverse cardiovascular event occurred in 15 (5.5%) patients assigned to degarelix and 11 (4.1%) patients assigned to leuprolide (hazard ratio, 1.28 [95% CI, 0.59-2.79]; P=0.53).ConclusionsPRONOUNCE (A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease) is the first, international, randomized clinical trial to prospectively compare the cardiovascular safety of a GnRH antagonist and a GnRH agonist in patients with prostate cancer. The study was terminated prematurely because of the smaller than planned number of participants and events, and no difference in major adverse cardiovascular events at 1 year between patients assigned to degarelix or leuprolide was observed. The relative cardiovascular safety of GnRH antagonists and agonists remains unresolved. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02663908.

Published
2021

7. Consistencies in Follow-up After Radical Cystectomy for Bladder Cancer: A Framework Based on Expert Practices Collaboratively Developed by the European Association of Urology Bladder Cancer Guideline Panels

Author

Mertens, Laura S., Bruins, Harman Maxim, Contieri, Roberto, Babjuk, Marek, Rai, Bhavan P., Puig, Albert Carrión, Escrig, Jose Luis Dominguez, Gontero, Paolo, van der Heijden, Antoine G., Liedberg, Fredrik, Martini, Alberto, Masson-Lecomte, Alexandra, Meijer, Richard P., Mostafid, Hugh, Neuzillet, Yann, Pradere, Benjamin, Redlef, John, van Rhijn, Bas W.G., Rouanne, Matthieu, Rouprêt, Morgan, Sæbjørnsen, Sæbjørn, Seisen, Thomas, Shariat, Shahrokh F., Soria, Francesco, Soukup, Viktor, Thalmann, George, Xylinas, Evanguelos, Mariappan, Paramananthan, and Alfred Witjes, J.

Published
2024
Full Text
View/download PDF

8. Mapping European Association of Urology Guideline Practice Across Europe: An Audit of Androgen Deprivation Therapy Use Before Prostate Cancer Surgery in 6598 Cases in 187 Hospitals Across 31 European Countries

Author

Heidegger, Isabel, Resch, Johannes Mischinger Irene, Turba, Simon, Zeder, Robin, Lodeta, Braninimir, Van Praet, Charles, Ghysel, Christophe, Arentsen, Harm C., Beysens, Matthias, Vinckier, Marie-Hélène, Mottrie, Alexandre, de Groote, Ruben, Timev, Aleksandar Ivanov, Georgiev, Marincho Ivanov, Yanev, Krassimir Prodanov, Mladenov, Boris, Ivanov, Atanas Slavchev, Antonov, Petar, Valkanov, Stanislav, Tomašković, Igor, Kulis, Tomislav, Bokarica, Pero, Pavlović, Oliver, Krajina, Vinko, Situm, Marijan, Boban, Toni, Soric, Tomislav, Vidic, Ivan, Benko, Goran, Peršec, Zoran, Sović, Tomislav, Zachoval, Roman, Stejskal, Jiri, Capoun, Otakar, Pitra, Tomáš, Gojdič, Marek, Babjuk, Marek, Novák, Vojtěch, Grepl, Michal, Broul, Marek, Novák, Jan, Lund, Lars, Nordström Joensen, Ulla, Borre, Michael, Veskimäe, Priit, Baum, Peep, Tamm, Toomas, Okas, Rauno, Jämsä, Pyry, Lahdensuo, Kanerva, Siltari, Sirkku, Seikkula, Heikki, Palmberg, Christian, Isotalo, Taina, Fiard, Gaelle, Verrier, Cecile, Wiedemann, Laura, Lecornet, Emilie, Leon, Priscilla, Millet, Clementine, Ponzio, Charles, Ploussard, Guillaume, Xylinas, Evanguelos, Ingels, Alexandre, Bigot, Pierre, Le Corre, Vincent, Audenet, François, Berg, Sebastian, Palisaar, Rein-Jueri, Heidenreich, Axel, Seelemeyer, Felix, Krege, Susanne, Leyh-Bannurah, Sami-Ramzi, Witt, Jörn H., Abdirahman, Ayanle, Truß, Michael C., Kranz, Jennifer, Andreas, Karagiannis, Vassileios, Tzortzis, Andreas, Andreou, Paparidis, Spyridon, Davis, Nikolaos Ferakis Niall F., Keane, Kevin G., Fuentes, Adrian, Scuderi, Simone, Barletta, Francesco, Manfredi, Matteo, Porpiglia, Francesco, Cerruto, Maria Angela, Antonelli, Alessandro, Esperto, Francesco, Rossanese, Marta, Veneziano, Domenico, Castelli, Tommaso, La Rocca, Roberto, Scarcia, Marcello, Mantica, Guglielmo, Rebuffo, Silvia, Pomara, Giorgio, Pavan, Nicola, Silvestri, Tommaso, Reale, Giulio Francesco, Polara, Andrea, Falagario, Ugo Giovanni, Carrieri, Giuseppe, Ferrari, Giovanni, Brausi, Maurizio, Orecchia, Luca, Annino, Filippo, Kazlauskas, Gražvydas, Stavridis, Sotir, Radovic, Nenad, Vukovic, Marko, van der Slot, Margaretha Adriana, Bruins, Harman Maxim, van Oort, Inge, Witjes, Fred, van der Poel, Henk, Beisland, Christian, Lilleåsenm, Gunder, Müller, Stig, Haug, Erik S., Dimmen, Magne, Czech, Anna K., Nyk, Lukasz, Jaskulski, Jaroslaw, Ratajczyk, Krzysztof, Azevedo, Nuno, Braga, Isaac, Pereira, João, Lúcio, Rui, Pina, João, da Silva, Edgar Miguel Calvo Loureiro Tavares, Furriel, Frederico, Mota, Paulo, Rodrigues, Miguel, Radavoi, George Daniel, Crisan, Nicolae, Andras, Iulia, Robert, Stoica, Bratu, Ovidiu, Surcel, Cristian, Kotov, Sergei, Malkhasyan, Vigen, Petrov, Sergei, Reva, Sergei, Bumbasirevic, Uros, Kováčik, Viktor, Perečinský, Ivan, Rybár, Ľuboš, Šulgan, Ján, Briš, Lukáš, Jursová, Katarína, Chovan, Miroslav, Kička, Tomáš, Taskovska, Milena, Kovačič, Rok, Miklavžina, Andraž, Alvarez-Maestro, Mario, De Castro, Javier Mayor, Aragón-Chamizo, Juan, Sutil, Raquel Sopeña, Perrello, Carmen Garau, Vilaseca, Antoni, Perez, Jorge Huguet, Ovide, Julia Aumatell, Planas, Jacques, Borque-Fernando, Angel, Sánchez-Izquierdo, Elena, Jimenez, Jose Luis Marenco, Lendínez-Cano, Guillermo, Puche-Sanz, Ignacio, Garcia-Baquero, Rodrigo, Esteban, Mario Domínguez, Pérez-Fentes, Daniel, Serván, Patricia Parra, Koskela, Lotta Renström, Stranne, Johan, Scholtz, Bianca, Torbrand, Christian, Wagenius, Magnus, Ugge, Henrik, Örtegren, Joakim, Langenauer, Janine, Zumstein, Valentin, Schmid, Hans Peter, Rieken, Malte, Saba, Karim, Strebel, Raeto T., Mortezavi, Ashkan, Rentsch, Cyrill, Roth, Beat, Eberli, Daniel, Pascal, Oechslin, Auer, Rebecca, John, Hubert, Thalmann, George N., Baltacı, Sümer, Mungan, Aydın, Sözen, Sinan, Cetin, Serhat, Aslan, Guven, Türkeri, Levent, İzol, Volkan, Demirdağ, Çetin, Ozden, Sami Berk, Toktaş, Gökhan, Sarikaya, Şaban, Tinay, İlker, Müezzinoğlu, Talha, Erbatu, Oguzcan, Sagnak, Levent, Akdoğan, Bülent, Can, Cavit, Şahin, Hayrettin, Yazıcı, Cenk Murat, Volkov, Serhii, Shulyak, Olexandr, Douglas, David, Hemmant, Joshua, El-Taji, Omar, Ahmad, Imran, Nalagatla, Sarika, Janebdar, Husay, Veeratterapillay, Rajan, Rai, Bhavan, Conroy, Samantha, Cumberbatch, Marcus, Malde, Sachin, MacLennan, Steven, Duncan, Eilidh, Dunsmore, Jennifer, Fullwood, Louise, Lumen, Nicolaas, Plass, Karin, Ribal, Maria J., Roobol, Monique J., Nieboer, Daan, Schouten, Natasha, Skolarus, Ted A., Smith, Emma Jane, N'Dow, James, Mottet, Nicolas, and Briganti, Alberto

Published
2023
Full Text
View/download PDF

11. Comparative Outcomes of Primary Versus Recurrent High-risk Non–muscle-invasive and Primary Versus Secondary Muscle-invasive Bladder Cancer After Radical Cystectomy: Results from a Retrospective Multicenter Study

Author

Grossmann, Nico C., Rajwa, Pawel, Quhal, Fahad, König, Frederik, Mostafaei, Hadi, Laukhtina, Ekaterina, Mori, Keiichiro, Katayama, Satoshi, Motlagh, Reza Sari, Fankhauser, Christian D., Mattei, Agostino, Moschini, Marco, Chlosta, Piotr, van Rhijn, Bas W.G., Teoh, Jeremy Y.C., Compérat, Eva, Babjuk, Marek, Abufaraj, Mohammad, Karakiewicz, Pierre I., Shariat, Shahrokh F., and Pradere, Benjamin

Published
2022
Full Text
View/download PDF

12. Association of patients’ sex with treatment outcomes after intravesical bacillus Calmette–Guérin immunotherapy for T1G3/HG bladder cancer

Author

D’Andrea, David, Soria, Francesco, Grotenhuis, Anne J., Cha, Eugene K., Malats, Nuria, Di Stasi, Savino, Joniau, Steven, Cai, Tommaso, van Rhijn, Bas W. G., Irani, Jaques, Karnes, Jeffrey, Varkarakis, John, Baniel, Jack, Palou, Joan, Babjuk, Marek, Spahn, Martin, Ardelt, Peter, Colombo, Renzo, Serretta, Vincenzo, Dalbagni, Guido, Gontero, Paolo, Bartoletti, Riccardo, Larré, Stephane, Malmstrom, Per-Uno, Sylvester, Richard, and Shariat, Shahrokh F.

Published
2021
Full Text
View/download PDF

13. Clinical and molecular response to alpha1‐oleate treatment in patients with bladder cancer.

Author

Haq, Farhan, Sabari, Samudra, Háček, Jaromir, Brisuda, Antonín, Ambite, Ines, Cavalera, Michele, Esmaeili, Parisa, Wan, Murphy Lam Yim, Ahmadi, Shahram, Babjuk, Marek, and Svanborg, Catharina

Subjects
CELL death inhibition, INTRAVESICAL administration, CANCER genes, GENE regulatory networks, RNA sequencing, BLADDER cancer
Abstract

Background: The tumoricidal complex alpha1‐oleate targets bladder cancer cells, triggering rapid, apoptosis‐like tumor cell death. Clinical effects of alpha1‐oleate were recently observed in patients with non‐muscle invasive bladder cancer (NMIBC), using a randomized, placebo‐controlled study protocol. Aims: To investigate if there are dose‐dependent effects of alpha1‐oleate. Materials and Methods: Here, patients with NMIBC were treated by intravesical instillation of increasing concentrations of alpha1‐oleate (1.7, 8.5, or 17 mM) and the treatment response was defined relative to a placebo group. Results: Strong, dose‐dependent anti‐tumor effects were detected in alpha1‐oleate treated patients for a combination of molecular and clinical indicators; a complete or partial response was detected in 88% of tumors treated with 8.5 mM compared to 47% of tumors treated with 1.7 mM of alpha1‐oleate. Uptake of alpha1‐oleate by the tumor triggered rapid shedding of tumor cells into the urine and cell death by an apoptosis‐like mechanism. RNA sequencing of tissue biopsies confirmed the activation of apoptotic cell death and strong inhibition of cancer gene networks, including bladder cancer related genes. Drug‐related side effects were not recorded, except for local irritation at the site of instillation. Discussion and Conclusions: These dose‐dependent anti‐tumor effects of alpha1‐oleate are promising and support the potential of alpha1‐oleate treatment in patients with NMIBC. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. An International Collaborative Consensus Statement on En Bloc Resection of Bladder Tumour Incorporating Two Systematic Reviews, a Two-round Delphi Survey, and a Consensus Meeting

Author

Teoh, Jeremy Yuen-Chun, MacLennan, Steven, Chan, Vinson Wai-Shun, Miki, Jun, Lee, Hsiang-Ying, Chiong, Edmund, Lee, Lui-Shiong, Wei, Yong, Yuan, Yuhong, Yu, Chun-Pong, Chow, Wing-Kie, Poon, Darren Ming-Chun, Chan, Ronald, Lai, Fernand, Ng, Chi-Fai, Breda, Alberto, Kramer, Mario Wolfgang, Malavaud, Bernard, Mostafid, Hugh, Herrmann, Thomas, and Babjuk, Marek

Published
2020
Full Text
View/download PDF

17. EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort†: Under the Auspices of the EAU-ESMO Guidelines Committees

Author

Witjes, J. Alfred, Babjuk, Marek, Bellmunt, Joaquim, Bruins, H. Maxim, De Reijke, Theo M., De Santis, Maria, Gillessen, Silke, James, Nicholas, Maclennan, Steven, Palou, Juan, Powles, Tom, Ribal, Maria J., Shariat, Shahrokh F., Der Kwast, Theo Van, Xylinas, Evanguelos, Agarwal, Neeraj, Arends, Tom, Bamias, Aristotle, Birtle, Alison, Black, Peter C., Bochner, Bernard H., Bolla, Michel, Boormans, Joost L., Bossi, Alberto, Briganti, Alberto, Brummelhuis, Iris, Burger, Max, Castellano, Daniel, Cathomas, Richard, Chiti, Arturo, Choudhury, Ananya, Compérat, Eva, Crabb, Simon, Culine, Stephane, De Bari, Berardino, De Blok, Willem, J.L. De Visschere, Pieter, Decaestecker, Karel, Dimitropoulos, Konstantinos, Dominguez-Escrig, Jose L., Fanti, Stefano, Fonteyne, Valerie, Frydenberg, Mark, Futterer, Jurgen J., Gakis, Georgios, Geavlete, Bogdan, Gontero, Paolo, Grubmüller, Bernhard, Hafeez, Shaista, Hansel, Donna E., Hartmann, Arndt, Hayne, Dickon, Henry, Ann M., Hernandez, Virginia, Herr, Harry, Herrmann, Ken, Hoskin, Peter, Huguet, Jorge, Jereczek-Fossa, Barbara A., Jones, Rob, Kamat, Ashish M., Khoo, Vincent, Kiltie, Anne E., Krege, Susanne, Ladoire, Sylvain, Lara, Pedro C., Leliveld, Annemarie, Linares-Espinós, Estefania, Løgager, Vibeke, Lorch, Anja, Loriot, Yohann, Meijer, Richard, Mir, M. Carmen, Moschini, Marco, Mostafid, Hugh, Müller, Arndt-Christian, Müller, Christoph R., N'Dow, James, Necchi, Andrea, Neuzillet, Yann, Oddens, Jorg R., Oldenburg, Jan, Osanto, Susanne, J.G. Oyen, Wim, Pacheco-Figueiredo, Luís, Pappot, Helle, Patel, Manish I., Pieters, Bradley R., Plass, Karin, Remzi, Mesut, Retz, Margitta, Richenberg, Jonathan, Rink, Michael, Roghmann, Florian, Rosenberg, Jonathan E., Rouprêt, Morgan, Rouvière, Olivier, Salembier, Carl, Salminen, Antti, Sargos, Paul, Sengupta, Shomik, Sherif, Amir, Smeenk, Robert J., Smits, Anita, Stenzl, Arnulf, Thalmann, George N., Tombal, Bertrand, Turkbey, Baris, Lauridsen, Susanne Vahr, Valdagni, Riccardo, Van Der Heijden, Antoine G., Van Poppel, Hein, Vartolomei, Mihai D., Veskimäe, Erik, Vilaseca, Antoni, Rivera, Franklin A. Vives, Wiegel, Thomas, Wiklund, Peter, Williams, Andrew, Zigeuner, Richard, and Horwich, Alan

Published
2020
Full Text
View/download PDF

19. Bladder cancer therapy using a conformationally fluid tumoricidal peptide complex

Author

Brisuda, Antonín, Ho, James C. S., Kandiyal, Pancham S., Ng, Justin T-Y., Ambite, Ines, Butler, Daniel S. C., Háček, Jaromir, Wan, Murphy Lam Yim, Tran, Thi Hien, Nadeem, Aftab, Tran, Tuan Hiep, Hastings, Anna, Storm, Petter, Fortunati, Daniel L., Esmaeili, Parisa, Novotna, Hana, Horňák, Jakub, Mu, Y. G., Mok, K. H., Babjuk, Marek, and Svanborg, Catharina

Published
2021
Full Text
View/download PDF

20. Discrepancy Between European Association of Urology Guidelines and Daily Practice in the Management of Non–muscle-invasive Bladder Cancer: Results of a European Survey

Author

Hendricksen, Kees, Aziz, Atiqullah, Bes, Perrine, Chun, Felix K.-H., Dobruch, Jakub, Kluth, Luis A., Gontero, Paolo, Necchi, Andrea, Noon, Aidan P., van Rhijn, Bas W.G., Rink, Michael, Roghmann, Florian, Rouprêt, Morgan, Seiler, Roland, Shariat, Shahrokh F., Qvick, Brian, Babjuk, Marek, and Xylinas, Evanguelos

Published
2019
Full Text
View/download PDF

21. Similar immune responses to alpha1‐oleate and Bacillus Calmette–Guérin treatment in patients with bladder cancer.

Author

Ahmadi, Shahram, Ambite, Ines, Brisuda, Antonín, Háček, Jaromír, Haq, Farhan, Sabari, Samudra, Vanarsa, Kamala, Mohan, Chandra, Babjuk, Marek, and Svanborg, Catharina

Subjects
BLADDER cancer, BCG immunotherapy, NON-muscle invasive bladder cancer, IMMUNE response, CANCER patients, END of treatment
Abstract

Background: The molecular content of urine is defined by filtration in the kidneys and by local release from tissues lining the urinary tract. Pathological processes and different therapies change the molecular composition of urine and a variety of markers have been analyzed in patients with bladder cancer. The response to BCG immunotherapy and chemotherapy has been extensively studied and elevated urine concentrations of IL‐1RA, IFN‐α, IFN‐γ TNF‐α, and IL‐17 have been associated with improved outcome. Methods: In this study, the host response to intravesical alpha 1‐oleate treatment was characterized in patients with non‐muscle invasive bladder cancer by proteomic and transcriptomic analysis. Results: Proteomic profiling detected a significant increase in multiple cytokines in the treatment group compared to placebo. The innate immune response was strongly activated, including IL‐1RA and pro‐inflammatory cytokines in the IL‐1 family (IL‐1α, IL‐1β, IL‐33), chemokines (MIP‐1α, IL‐8), and interferons (IFN‐α2, IFN‐γ). Adaptive immune mediators included IL‐12, Granzyme B, CD40, PD‐L1, and IL‐17D, suggesting broad effects of alpha 1‐oleate treatment on the tumor tissues. Conclusions: The cytokine response profile in alpha 1‐oleate treated patients was similar to that reported in BCG treated patients, suggesting a significant overlap. A reduction in protein levels at the end of treatment coincided with inhibition of cancer‐related gene expression in tissue biopsies, consistent with a positive treatment effect. Thus, in addition to killing tumor cells and inducing cell detachment, alpha 1‐oleate is shown to activate a broad immune response with a protective potential. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

23. Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non–muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review

Author

Soukup, Viktor, Čapoun, Otakar, Cohen, Daniel, Hernández, Virginia, Babjuk, Marek, Burger, Max, Compérat, Eva, Gontero, Paolo, Lam, Thomas, MacLennan, Steven, Mostafid, A. Hugh, Palou, Joan, van Rhijn, Bas W.G., Rouprêt, Morgan, Shariat, Shahrokh F., Sylvester, Richard, Yuan, Yuhong, and Zigeuner, Richard

Published
2017
Full Text
View/download PDF

27. Prognostic value of the systemic inflammation modified Glasgow prognostic score in patients with upper tract urothelial carcinoma (UTUC) treated with radical nephroureterectomy: Results from a large multicenter international collaboration

Author

Soria, Francesco, Giordano, Andrea, D'Andrea, David, Moschini, Marco, Rouprêt, Morgan, Margulis, Vitaly, Karakiewicz, Pierre I., Briganti, Alberto, Bensalah, Karim, Mathieu, Romain, Chlosta, Piotr, Babjuk, Marek, Glybochko, Petr V., Enikeev, Dmitry V., Remzi, Mesut, Gust, Kilian, Gontero, Paolo, and Shariat, Shahrokh F.

Published
2020
Full Text
View/download PDF

28. Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group.

Author

Kamat, Ashish M., Apolo, Andrea B., Babjuk, Marek, Bivalacqua, Trinity J., Black, Peter C., Buckley, Roger, Campbell, Matthew T., Compérat, Eva, Efstathiou, Jason A., Grivas, Petros, Gupta, Shilpa, Kurtz, Neil J., Lamm, Donald, Lerner, Seth P., Li, Roger, McConkey, David J., Palou Redorta, Joan, Powles, Thomas, Psutka, Sarah P., and Shore, Neal

Published
2023
Full Text
View/download PDF

31. Long‐term prevention of bladder cancer progression by alpha1‐oleate alone or in combination with chemotherapy.

Author

Hien, Tran Thi, Ambite, Ines, Wan, Murphy Lam Yim, Cavalera, Michele, Esmaeili, Parisa, Chaudhuri, Arunima, Sabari, Samudra, Babjuk, Marek, and Svanborg, Catharina

Subjects
BLADDER cancer, NON-muscle invasive bladder cancer, COMBINATION drug therapy, CANCER prevention, CANCER invasiveness, INTRAVESICAL administration
Abstract

Bladder cancer is common and one of the most costly cancer forms, due to a lack of curative therapies. Recently, clinical safety and efficacy of the alpha1‐oleate complex was demonstrated in a placebo‐controlled study of nonmuscle invasive bladder cancer. Our study investigated if long‐term therapeutic efficacy is improved by repeated treatment cycles and by combining alpha1‐oleate with low‐dose chemotherapy. Rapidly growing bladder tumors were treated by intravesical instillation of alpha1‐oleate, Epirubicin or Mitomycin C alone or in combination. One treatment cycle arrested tumor growth, with a protective effect lasting at least 4 weeks in mice receiving 8.5 mM of alpha1‐oleate alone or 1.7 mM of alpha‐oleate combined with Epirubicin or Mitomycin C. Repeated treatment cycles extended protection, defined by a lack of bladder pathology and a virtual absence of bladder cancer‐specific gene expression. Synergy with Epirubicin was detected at the lower alpha1‐oleate concentration and in vitro, alpha1‐oleate was shown to enhance the uptake and nuclear translocation of Epirubicin, by tumor cells. Effects at the chromatin level affecting cell proliferation were further suggested by reduced BrdU incorporation. In addition, alpha1‐oleate triggered DNA fragmentation, defined by the TUNEL assay. The results suggest that bladder cancer development may be prevented long‐term in the murine model, by alpha1‐oleate alone or in combination with low‐dose Epirubicin. In addition, the combination of alpha1‐oleate and Epirubicin reduced the size of established tumors. Exploring these potent preventive and therapeutic effects will be of immediate interest in patients with bladder cancer. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

36. COMPLICATION RATES AFTER RADICAL CYSTECTOMY AFTER RADIOTHERAPY: AN INTERNATIONAL, MULTICENTER RETROSPECTIVE STUDY ON 609 CASES: PD12-12

Author

Gontero, Paolo, Pisano, Francesca, Joniau, Steven, Albersen, Maarten, Battaglia, Antonino, Destefanis, Paolo, Colombo, Renzo, Briganti, Alberto, Pellucchi, Federico, Burgio, Giusy, Van Rhijn, Bas, Fransen Van de Putte, Elies E., Esquena, Salvador, Palou, Juan, Babjuk, Marek, Fritsche, Hans Martin, Mayr, Roman, Albers, Peter, Niegisch, Guenter, De la Taille, Alexandre, Masson-Lecomte, Alexandra, Roupret, Morgan, Cai, Tommaso, Witjes, Alfred J, Bruins, Max, Baniel, Jack, Mano, Roy, Brausi, Maurizio, Lapini, Alberto, Sessa, Francesco, Irani, Jaques, Stenzl, Arnulf, Gakis, Georgios, Karnes, Jeffrey R., Zattoni, Fabio, Scherr, Douglas, OʼMalley, Padraic, Shariat, Shahrokh F, Black, Peter, Abdi, Hamidreza, Matveev, Vsevolod B, Samuseva, Olga I, Peters, Maria V, Parekh, Dipen J, Gonzalgo, Mark, Atiquallah, Aziz, Fish, Margit, and Rink, Michael

Published
2016
Full Text
View/download PDF

38. PD29-12 COMPARISON OF ONCOLOGICAL OUTCOMES OF DISTAL URETERAL ≤PT2 UROTHELIAL CARCINOMA MANAGED BY NEPHROURETERECTOMY, SEGMENTAL URETERECTOMY OR ENDOSCOPIC SURGERY

Author

Nison, Laurent, Colin, Pierre, Remzi, Mesut, Shariat, Shahrokh F., Klatte, Tobias, Yakoubi, Rachid, Bozzini, Gregory, Capitanio, Umberto, Babjuk, Marek, Merseburger, Axel. S, Cha, Eugene, Fritsche, Hans Martin, Novara, Giacomo, Montorsi, Francesco, Hora, Milan, and Rouprêt, Morgan

Published
2015
Full Text
View/download PDF

39. PD17-11 THE IMPACT OF DIFFERENT BCG STRAINS ON OUTCOME IN A LARGE COHORT OF T1G3 PATIENTS TREATED WITH BCG.

Author

Gontero, Paolo, Sylvester, Richard, Pisano, Francesca, Dalbagni, Guido, Shariat, Sharok, Karnes, Jeffrey, joniau, Steven, Serretta, Vincenzo, Palou, Jouan, Di Stasi, Savino, Larrè, Stephane, Colombo, Renzo, Babjuk, Marek, Malmstrom, Per Uno, Irani, Jaques, Malats, Nuria, Baniel, Jack, Cai, Tommaso, Cha, Eugene, Ardelt, Petere, varkarakis, Jhon, Bartoletti, Riccardo, Sphan, Marthin, and Witjes, J Alfred

Published
2015
Full Text
View/download PDF

40. The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non–muscle-invasive bladder cancer

Author

Witjes, J. Alfred, Dalbagni, Guido, Karnes, Robert J., Shariat, Shahrokh, Joniau, Steven, Palou, Joan, Serretta, Vincenzo, Larré, Stéphane, di Stasi, Savino, Colombo, Renzo, Babjuk, Marek, Malmström, Per-Uno, Malats, Nuria, Irani, Jacques, Baniel, Jack, Cai, Tommaso, Cha, Eugene, Ardelt, Peter, Varkarakis, John, Bartoletti, Riccardo, Spahn, Martin, Pisano, Francesca, Gontero, Paolo, and Sylvester, Richard

Published
2016
Full Text
View/download PDF

41. Predictors of Survival in Patients With Soft Tissue Surgical Margin Involvement at Radical Cystectomy

Author

Xylinas, Evanguelos, Rink, Michael, Novara, Giacomo, Green, David A., Clozel, Thomas, Fritsche, Hans-Martin, Guillonneau, Bertrand, Lotan, Yair, Kassouf, Wassim, Tilki, Derya, Babjuk, Marek, Karakiewicz, Pierre I., Montorsi, Francesco, Abdennabi, Joual, Trinh, Quoc D., Svatek, Robert S., Scherr, Douglas S., Zerbib, Marc, and Shariat, Shahrokh F.

Published
2013
Full Text
View/download PDF

42. Corrigendum to ‘EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees’ [European Urology 77 (2020) 223–250]

Author

Witjes, J. Alfred, Babjuk, Marek, Bellmunt, Joaquim, Bruins, H. Maxim, De Reijke, Theo M., De Santis, Maria, Gillessen, Silke, James, Nicholas, Maclennan, Steven, Palou, Juan, Powles, Tom, Ribal, Maria J., Shariat, Shahrokh F., Van Der Kwast, Theo, Xylinas, Evanguelos, Agarwal, Neeraj, Arends, Tom, Bamias, Aristotle, Birtle, Alison, Black, Peter C., Bochner, Bernard H., Bolla, Michel, Boormans, Joost L., Bossi, Alberto, Briganti, Alberto, Brummelhuis, Iris, Burger, Max, Castellano, Daniel, Cathomas, Richard, Chiti, Arturo, Choudhury, Ananya, Compérat, Eva, Crabb, Simon, Culine, Stephane, De Bari, Berardino, De Blok, Willem, De Visschere, Pieter J.L., Decaestecker, Karel, Dimitropoulos, Konstantinos, Dominguez-Escrig, Jose L., Fanti, Stefano, Fonteyne, Valerie, Frydenberg, Mark, Futterer, Jurgen J., Gakis, Georgios, Geavlete, Bogdan, Gontero, Paolo, Grubmüller, Bernhard, Hafeez, Shaista, Hansel, Donna E., Hartmann, Arndt, Hayne, Dickon, Henry, Ann M., Hernandez, Virginia, Herr, Harry, Herrmann, Ken, Hoskin, Peter, Huguet, Jorge, Jereczek-Fossa, Barbara A., Jones, Rob, Kamat, Ashish M., Khoo, Vincent, Kiltie, Anne E., Krege, Susanne, Ladoire, Sylvain, Lara, Pedro C., Leliveld, Annemarie, Linares-Espinós, Estefania, Løgager, Vibeke, Lorch, Anja, Loriot, Yohann, Meijer, Richard, Mir, M. Carmen, Moschini, Marco, Mostafid, Hugh, Müller, Arndt-Christian, Müller, Christoph R., N’Dow, James, Necchi, Andrea, Neuzillet, Yann, Oddens, Jorg R., Oldenburg, Jan, Osanto, Susanne, Oyen, Wim J.G., Pacheco-Figueiredo, Luís, Pappot, Helle, Patel, Manish I., Pieters, Bradley R., Plass, Karin, Remzi, Mesut, Retz, Margitta, Richenberg, Jonathan, Rink, Michael, Roghmann, Florian, Rosenberg, Jonathan E., Rouprêt, Morgan, Rouvière, Olivier, Salembier, Carl, Salminen, Antti, Sargos, Paul, Sengupta, Shomik, Sherif, Amir, Smeenk, Robert J., Smits, Anita, Stenzl, Arnulf, Thalmann, George N., Tombal, Bertrand, Turkbey, Baris, Lauridsen, Susanne Vahr, Valdagni, Riccardo, Van Der Heijden, Antoine G., Van Poppel, Hein, Vartolomei, Mihai D., Veskimäe, Erik, Vilaseca, Antoni, Rivera, Franklin A. Vives, Wiegel, Thomas, Wiklund, Peter, Willemse, Peter-Paul M., Williams, Andrew, Zigeuner, Richard, and Horwich, Alan

Published
2020
Full Text
View/download PDF

43. European Association of Urology Guidelines Office Rapid Reaction Group: An Organisation-wide Collaborative Effort to Adapt the European Association of Urology Guidelines Recommendations to the Coronavirus Disease 2019 Era

Author

Ribal, Maria J., Cornford, Philip, Briganti, Alberto, Knoll, Thomas, Gravas, Stavros, Babjuk, Marek, Harding, Christopher, Breda, Alberto, Bex, Axel, Rassweiler, Jens J., Gözen, Ali S., Pini, Giovannalberto, Liatsikos, Evangelos, Giannarini, Gianluca, Mottrie, Alex, Subramaniam, Ramnath, Sofikitis, Nikolaos, Rocco, Bernardo M.C., Xie, Li-Ping, Witjes, J. Alfred, Mottet, Nicolas, Ljungberg, Börje, Rouprêt, Morgan, Laguna, Maria P., Salonia, Andrea, Bonkat, Gernot, Blok, Bertil F.M., Türk, Christian, Radmayr, Christian, Kitrey, Noam D., Engeler, Daniel S., Lumen, Nicolaas, Hakenberg, Oliver W., Watkin, Nick, Hamid, Rizwan, Olsburgh, Jonathon, Darraugh, Julie, Shepherd, Robert, Smith, Emma-Jane, Chapple, Christopher R., Stenzl, Arnulf, Van Poppel, Hendrik, Wirth, Manfred, Sønksen, Jens, and N’Dow, James

Published
2020
Full Text
View/download PDF

44. THE IMPACT OF RE-TUR ON CLINICAL OUTCOMES IN A LARGE COHORT OF T1G3 PATIENTS TREATED WITH BCG.: MP56-16

Author

gontero, paolo, Sylvester, richard, Pisano, Francesca, Joniau, Steven, Van der Eeckt, Kathy, Serretta, Vincenzo, Larrè, Stephane, Di Stasi, Savino, van Rhjin, bas, Witjes, Alfred, grotenhuis, anne, Kimeney, Bart, colombo, renzo, Briganti, Alberto, Babjuk, Marek, soukup, Viktor, Malmstrom, Per Uno, Irani, Jaques, Malats, Nuria, Baniel, Jack, Mano, Roy, Cai, Tommaso, cha, eugene, Ardelt, Peter, varkarakis, John, Bartoletti, Riccardo, Spahn, Martin, Palou, jouan, Dalbagni, Guido, Xylinas, Evangelous, Shariat, Sharok, and karnes, Jeffrey R.

Published
2014
Full Text
View/download PDF

45. COMPARISON OF THE EORTC TABLES AND THE NEWLY INTRODUCED EAU CATEGORIES FOR RISK STRATIFICATION OF PATIENTS WITH NON-MUSCLE-INVASIVE BLADDER CANCER: MP56-07

Author

Rieken, Malte, Shariat, Shahrokh, Al Hussein Al Awamlh, Bashir, Kluth, Luis, Crivelli, Joseph, Chrystal, James, Faison, Talia, Lotan, Yair, Karakiewicz, Pierre, Babjuk, Marek, Fajkovic, Harun, Seitz, Christian, Klatte, Tobias, Pycha, Armin, Bachmann, Alexander, Gönen, Mithat, and Xylinas, Evanguelos

Published
2014
Full Text
View/download PDF

47. PROGNOSTIC FACTORS AND RISK GROUPS IN T1G3 PATIENTS INITIALLY TREATED WITH BCG: RESULTS OF A MULTICENTER RETROSPECTIVE SERIES IN 2530 PATIENTS: 1697

Author

Gontero, Paolo, Sylvester, Richard, Pisano, Francesca, Joniau, Steven, Van der Eeckt, kathy, serretta, vincenzo, larré, stephane, di stasi, savino, Van Rhjin, Bas, witjes, alfred, Grotenhuis, Anne, Colombo, Renzo, Briganti, Alberto, Babjuk, Marek, Soukup, Viktor, Malmstrom, Per Uno, Irani, Jaques, Malats, Nuria, Baniel, Jack, Mano, Roy, Cai, Tommaso, Cha, Eugene, Ardelt, Peter, Varkarakis, John, Bartoletti, Riccardo, Spahn, Martin, Palou, Juan, Dalbagni, Guido, Shariat, Sharok, and Karnes, Jeffrey

Published
2013
Full Text
View/download PDF

48. Obesity is associated with worse oncological outcomes in patients treated with radical cystectomy

Author

Chromecki, Thomas F., Cha, Eugene K., Fajkovic, Harun, Rink, Michael, Ehdaie, Behfar, Svatek, Robert S., Karakiewicz, Pierre I., Lotan, Yair, Tilki, Derya, Bastian, Patrick J., Daneshmand, Siamak, Kassouf, Wassim, Durand, Matthieu, Novara, Giacomo, Fritsche, Hans-Martin, Burger, Maximilian, Izawa, Jonathan I., Brisuda, Antonin, Babjuk, Marek, Pummer, Karl, and Shariat, Shahrokh F.

Published
2013
Full Text
View/download PDF

49. Comparison of Clinicopathologic and Oncological Outcomes Between Transurethral En Bloc Resection and Conventional Transurethral Resection of Bladder Tumor: A Systematic Review, Meta-Analysis, and Network Meta-Analysis with Focus on Different Energy Sources

Author

Sari Motlagh, Reza, Rajwa, Pawel, Mori, Keiichiro, Laukhtina, Ekaterina, Aydh, Abdulmajeed, Katayama, Satoshi, Yanagisawa, Takafumi, König, Frederik, Grossmann, Nico C., Pradere, Benjamin, Mostafai, Hadi, Quhal, Fahad, Karakiewicz, Pierre I., Babjuk, Marek, and Shariat, Shahrokh F.

Subjects
TUMOR surgery, BLADDER cancer, WEB databases, SCIENCE databases, CLINICAL pathology, BAYESIAN analysis
Abstract

Introduction: It has been hypothesized that transurethral en bloc (TUEB) of bladder tumor offers benefits over conventional transurethral resection of bladder tumor (cTURBT). This study aimed to compare disease outcomes of TUEB and cTURBT with focus on the different energy sources. Methods: A systematic search was performed using PubMed and Web of Science databases in June 2021. Studies that compared the pathological (detrusor muscle presence), oncological (recurrence rates) efficacy, and safety (serious adverse events [SAEs]) of TUEB and cTURBT were included. Random- and fixed-effects meta-analytic models and Bayesian approach in the network meta-analysis was used. Results: Seven randomized clinical trials (RCTs) and seven non-RCTs (NRCT), with a total of 2092 patients. The pooled 3- and 12-month recurrence risk ratios (RR) of five and four NRCTs were 0.46 (95% CI 0.29–0.73) and 0.56 (95% CI 0.33–0.96), respectively. The pooled 3- and 12-month recurrence RRs of four and seven RCTs were 0.57 (95% CI 0.25–1.27) and 0.89 (95% CI 0.69–1.15), respectively. The pooled RR for SAEs such as prolonged hematuria and bladder perforation of seven RCTs was 0.16 (95% CI 0.06–0.41) in benefit of TUEB. Seven RCTs (n = 1077) met our eligibility criteria for network meta-analysis. There was no difference in 12-month recurrence rates between hybridknife, laser, and bipolar TUEB compared with cTURBT. Contrary, laser TUEB was significantly associated with lower SAEs compared with cTURBT. Surface under the cumulative ranking curve ranking analyses showed with high certainty that laser TUEB was the best treatment option to access all endpoints. Conclusion: While NRCTs suggested a recurrence-free benefit to TUEB compared with cTURBT, RCTs failed to confirm this. Conversely, SAEs were consistently and clinically significantly better for TUEB. Network meta-analyses suggested laser TUEB has the best performance compared with other energy sources. These early findings need to be confirmed and expanded upon. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results